Help
1106 Article Views
Publication Date: 31 Jul 2011
Journal: Clinical Medicine Reviews in Vascular Health
doi: 10.4137/CMRVH.S1570
Phosphodiesterase type 5 (PDE5) inhibitors are arguably the gold standard for treatment of erectile dysfunction in men. While all three PDE5 inhibitors approved for use in the U.S. are effective in treating ED, they possess different characteristics. Tadalafil differs from both sildenafil and vardenafil in its long half-life, which makes it ideal for daily dosing. This regimen has been shown to be effective over placebo, and studies suggest that it may be preferable by both partners over on-demand dosing. Side effects are typically mild in nature and infrequently lead to discontinuation of the drug. Once-daily dosing has also shown to be effective in ‘difficult-to-treat’ groups, such as diabetics and non-responders to on-demand therapy. The implementation of once-daily therapy represents a significant advancement in the understanding of male erectile dysfunction.
My laboratory has published several papers in Cell Communication Insights. In each case, reviewer comments were returned promptly; the suggested revisions were both fair and quite helpful, reflecting positively on the quality of the review. Once accepted, the editorial office provided clear and frequent updates on the progress of our manuscripts through each step of the publication process. When necessary, I had prompt email responses to my questions and the figure quality was exceptional. Keep up the outstanding work.Dr Paul J. Higgins (Director, Center for Cell Biology & Cancer Research, Albany Medical College, Albany, New York, USA) What Your Colleagues Say
Copyright © 2012 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)
FacebookGoogle+Twitter
PinterestTumblrYouTube